[
  {
    "name": "footnote",
    "path": "C:\\Users\\felip\\source\\repos\\visual_grounding_data_generation\\resources\\cloud_presentations\\2025-11-15-15-58-09_Neurizon_Market Access Strategy Weekly Check-in 11102025.pptx",
    "slide_number": 7,
    "slide_width": 960.0,
    "slide_height": 540.0,
    "selection_type": "shape",
    "shape_ids": [
      25
    ],
    "table_rows": "",
    "table_cols": "",
    "table_cells": "",
    "bbox": [
      [
        0.0507,
        0.8446,
        0.8928,
        0.0711
      ]
    ],
    "color_rgb": [
      [
        255,
        255,
        255
      ]
    ],
    "text": [
      "1. ATTRuby: Median OS 2-5 years depending on disease stage. Source: Naoto et al., Journal of the American Heart Association, 2024. Ojjaara: Median OS 2.1 years. Source: Green et al., MPN Hub, 2025. Zilbrysq: 86% survival at 5 years, 79% at 10 years. Source: Khateb et al., Frontiers in Neurology, 2025. Ctexli: Median OS > 5 years. Source: Nie et al., Orphanet J Rare Disease, 2014. Filspari, Vanrafia: Median kidney failure-free survival > 5 years. Source: McGrogan et al., Nephrol Dial Transplant., 2011. Iqirvo, Livdelzi: Median OS > 5 years. Source: Green et al., The Pharmaceutical Journal, 2023. Joenja: Median OS > 5 years. Source: Mahendran et al., Orphanet J Rare Disease, 2025. Alyftrek: Median OS > 5 years. Source: CF Foundation Patient Registry, 2025"
    ]
  }
]